Password Reset

Longevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643

First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest. First Longevity Limited does not give advice on the risks of investment and is not authorised to carry out investment business under the Financial Services and Markets Act 2000 (“FSMA”).

The content on this website has not been approved by an authorised person within the meaning of FSMA, for the purposes of section 21 of FSMA and reliance on information on this website for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of their property or other assets involved.

Users of this website should not treat its contents as constituting advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers authorised under FSMA who specialize in advising on such matters.

The information included in this website and Longevity.Technology System is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

The latest longevity science, investment, innovation and insight, delivered every morning.

First Name(Required)

Email Address(Required)

Contact Source

Unlock Longevity Biotech Report for FREE

$617BN - Annual global revenue by 2045
$30BN+ - Invested in under 2 years
3,036 - Therapeutics individually assessed

Access full report